Another promising agent is mobocertinib, an irreversible TKI targeting EGFR and HER2 exon 20 variants, which has been tested in pretreated NSCLC patients with EGFR exon 20 insertion mutations [49]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.